Abstract Purpose: DNA damage recognition and repair play a major role in risk for breast cancer.
It is well established that alterations of genes involved in DNA damage recognition and repair are associated with cancer risk. Mutations of genes in the DNA repair pathways, such as BRCA1, BRCA2 (1), and ATM (2) , confer an increased risk of breast cancer. However, the majority of familial breast cancers have yet to yield single causative mutations. It has been hypothesized that common genetic polymorphisms within DNA damage repair pathway genes may contribute to the development of familial breast cancer.
DNA is subject to continuous damage by exogenous chemical or physical agents or by endogenous byproducts of normal cellular metabolism. DNA damage can trigger cell cycle arrest and DNA repair or, when the damage is too severe for repair, cellular death by apoptosis. Long-term effects of DNA damage may lead to irreversible mutations, contributing to oncogenesis. Thus, compromised DNA repair function likely plays an important role in carcinogenesis and acts as a genetic risk factor for cancers, including breast cancer. Cells from patients with inherited syndromes, involving mutations in genes responsible for the integrity of the genome and chromosomal stability and associated with either cancer predisposition or accelerated senescence, display elevated frequencies of chromosomal aberrations (3 -5) . Several partially overlapping DNA repair pathways operate in mammals, including nucleotide excision repair, base excision repair, mismatch repair, and double-stranded break repair (DSBR; Fig. 1 ). Both BRCA1 and BRCA2 function in the DSBR pathways of the cell (Fig. 2) .
A large number of single nucleotide polymorphisms (SNP) in DNA repair genes have been identified. Single nucleotide alterations may influence protein expression or gene function either by directly leading to amino acid change and modification in protein function or through indirect epigenetic changes in synonymous or noncoding SNPs. Much of the genetic variation in the DNA repair capacity of the general population likely resides in common SNPs in DNA repair genes. Individual susceptibility to breast cancer may lie in variations in the ability of the cell to respond to DNA damage. Some studies have suggested that specific SNPs in genes in the DSBR pathway are associated with breast cancer risk including XRCC2 (6 -8) , XRCC4 (9) , ZNF350 (10, 11) , RAD51 (12) , RAD52, LIG4 (8) , and ATM (13) . A recent candidate gene study using
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Authors' Affiliations: Divisions of 1 Hematology and Oncology and 2 Geriatrics, Departments of Medicine, 3 Biomathematics, and 4 Human Genetics, David Geffen School of Medicine at University of California at Los Angeles; a population-based study design (14) systematically examined DSBR genes (164 SNPs in 20 DSBR genes) and found that none of these genes was associated with breast cancer after correcting for multiple testing. Our study also systematically examines DSBR genes (104 SNPs in 7 genes) including 13 genes examined by Pharoah et al. (14) but in a very differently ascertained sample of cases and controls.
Through the University of California at Los Angeles (UCLA) Familial Cancer Registry, we have access to a highly enriched population of individuals selected for their risk of familial breast cancer. Although some of these individuals carry BRCA1 or BRCA2 (BRCA1/2) mutations, the majority do not. The primary aim of this study is to examine selected SNPs in 17 important DNA-DSBR genes to determine their association with breast cancer in this high-risk population.
Materials and Methods
UCLA Familial Cancer Registry. Epidemiologic and clinical data and biological specimens for this study were collected from the UCLA Familial Cancer Registry and Genetic Evaluation Program. The program is a shared resource of the Jonsson Comprehensive Cancer Center, which was established to facilitate genetic, behavioral, and biological research. To be eligible for the Registry, both affected and unaffected participants must meet the following criteria: ages z18 years and either (a ) their family history must contain at least two firstor second-degree relatives with the same primary cancer or cancers that are known to be related (breast and ovarian) or (b) they have a personal/family history of known cancer genetic susceptibility (e.g., a mutation in BRCA1). The Registry began accepting participants in September 1998 and recruits new participants on an ongoing basis; the
Translational Relevance
It is well known that BRCA1 and BRCA2 mutations are strong risk factors for the development of hereditary breast and ovarian cancers.This study lends support to the notion that, in addition to BRCA1 and BRCA2, other genes involved in the double-stranded DNA repair pathway are linked with breast cancer. Most notably, polymorphisms in RAD21 and XRCC4 were found to be associated with breast cancer in a population in which both cases and controls were at high familial risk for breast cancer. Because the sample size is relatively small and the results cannot be extrapolated to predict risks in all women, these results must be viewed as preliminary. However, these results warrant validation in larger cohorts and contribute to the identification of genes associated with breast cancer. Further investigation of these genes may aid in prediction and prevention of breast cancer and in counseling individuals with a known family history of breast cancer. women in the current study were enrolled between April 1999 and December 2005 when this study was initiated. Men with similar medical histories or family backgrounds were excluded from this study due to small numbers in the Registry and their potentially different genetic risks of breast cancer. Further details of Registry recruitment and procedures have been discussed elsewhere (15, 16) .
Study patient population. All study subjects have given signed informed consent to participate in the Registry research protocol, which includes this and other studies and has been approved by the UCLA Institutional Review Board. As a result, specimens and questionnaire data could be used for this study without additional consent. We selected for analysis unrelated Caucasian women who either had breast cancer or breast and ovarian cancers or were unaffected (controls). See Results for details.
At enrollment, registry participants completed an initial questionnaire (covering demographics, personal health habits and health status, reproductive history, medication use, and family history of cancer). In addition, a certified genetic counselor (J.L.S.) interviewed participants and prepared a multigeneration pedigree containing all known geneticand cancer-related information on relatives. Questionnaires and pedigree data are updated annually.
A vial of whole blood was used for the DNA purification; the blood samples were processed according to the specified protocol and stored in the designated Revco -80jC freezer for the project located at UCLA Immunogenetics Center. Results from BRCA1 and BRCA2 testing were obtained for each participant via commercial clinical testing at Myriad Laboratories or in some cases outside of the United States. In some cases, where testing was limited to a specific familial mutation in BRCA1/2, we inferred that the individual was negative for the other.
SNP selection. Seventeen genes involved in the DNA-DSBR pathway were systematically selected for evaluation based on evidence for their role in either the homologous recombination repair or the nonhomologous end joining pathways as shown in Fig. 2 . When possible, we included known functional SNPs within the DNA-DSBR pathway and potentially functional SNPs such as amino acid-changing (nonsynonymous) SNPs. All the SNPs selected have a minor allele frequency >5% in the National Cancer Institute SNP 500 Project, 10 National Center for Biotechnology Information dbSNP, 11 and National Institute of Environmental Health Sciences GeneSNPs 12 as well as in the published literature.
The final set of SNPs used in the analysis was selected based on (a) successful genotyping on at least 75% of the Caucasian participants (see Genotyping Quality Control for details), (b) minor allele frequencies >0.10 in the unaffected Caucasian participant sample, (c) P values > 0.0050 from Hardy-Weinberg equilibrium testing in the unaffected Caucasian participant sample, (d) limited linkage disequilibrium among the SNPs in the unaffected Caucasian participant sample as defined by r 2 V 0.95 with all the other SNPs or selection as a tag SNP using Haploview Tagger algorithm (Haploview 4.0; refs. 17, 18) , and (e) availability of coding information through Applied Biosystems SNPlex technology. The resulting 104 SNPs that met these requirements are in or near 1 of 17 DNA-DSBR genes (Table 1) . SNPs were grouped into haplotype blocks using Haploview version 4.1 (denoted by brackets in Table 1 ). Haplotype blocks were defined by evidence of linkage disequilibrium greater than D ¶ of 0.95 as described by Gabriel et al (49) .
Whole-genome amplification. Genomic DNA was isolated from peripheral blood mononuclear cells using the Qiagen extraction method. The REPLI-g Midi Kit (Qiagen) was used for the wholegenome amplification according to the manufacturer's specifications. Briefly, 2.5 AL of each DNA sample was denatured by adding 2.5 AL denaturation buffer. After denaturation was stopped by the addition of 5.0 AL neutralization buffer, a master mix of 40 AL containing REPLI-g Midi reaction buffer and DNA polymerase was added to each reaction tube. The reaction tubes were incubated at 30jC for 16 h and 65jC for 3 min and 4jC on Applied Biosystems GeneAmp 9700. DNA concentration and yield was determined by Quant-iT PicoGreen dsDNA reagent kit (Invitrogen), and the fluorescence was measured in a BioTek FLX800 fluorescence microplate reader with excitation set at 480 nm and emission at 520 nm. The DNA concentration values were obtained by plotting the concentration of DNA standards (Ag/mL; X axis) against the fluorescence reading generated by the microplate reader (Y axis). The average product length was typically >10 kb (range, 2-100 kb) and yielded f40 Ag amplified DNA/50 AL reaction. As a verification of whole-genome amplification, we assayed the PON1 rs662 polymorphism using 14 pairs of original and amplified DNA samples. We found 100% concordance between the original DNA and the amplified DNA.
Genotyping assays. Genotypes were determined using the Applied Biosystems SNPlex assay (19) . This method assays SNP genotypes in 48 SNP PCR multiplexes using an oligonucleotide ligation process. Each SNP allele was ligated to an allele-specific oligonucleotide and then hybridized with a Zipchute probe with a mobility modifier and a fluorescent label, allowing the probe to be separated and detected by capillary electrophoresis. Detection was done on an Applied Biosystems 3730 DNA Analyzer, and data interpretation was done with the Applied Biosystems Genemapper software version 4.0, which uses a clustering algorithm with stringent quality checks to call genotypes. Only genotypes with a Genemapper quality score of >95% were passed. With the SNPlex genotyping assay, the UCLA Genotyping Core achieves an average call rate of 96%, a reproducibility rate of 99.7%, and a concordance rate of 99.8%. 13 Genotype concordance is validated by allelic discrimination assay on an Applied Biosystems 7900HT Fast Real-time PCR System.
Genotyping quality control. Before starting the genotyping assays, each whole-genome amplified DNA sample was run on an agarose gel to check DNA quality. Every SNP primer set was checked for performance by running it against an Applied Biosystems standard DNA set: SNPlex System Dried gDNA Plates Kit (PN 4362637).
All genotyping was done blindly to family structure and disease status (affected or unaffected by cancer). Genemapper genotyping was done by two different individuals: one individual doing the first scoring and the second individual checking the results obtained by the first scorer.
After genotype scoring using the Genemapper software, the data were exported to the SNP Core's Integrated Genetic Database. This database holds all the genotypes generated in the Core as well as pedigree information, phenotype data, and marker information such as heterozygosity, ethnic allele frequencies, and genetic and physical maps. This information is used in the data quality checks. All genotypes were checked for Hardy-Weinberg equilibrium and divergence from published allele frequencies. These checks were done across the entire sample, and also on individual genotyping runs, to identify any possible bad runs. Any markers, sample sets, or genotyping runs that gave suspect results on Hardy-Weinberg equilibrium or on any quality-control validation tests were manually rescored. If the problem persisted on manual rescoring, the assays were repeated. Questionable data that could not be resolved by reevaluation or rerunning were discarded.
When several members of the same family were genotyped, an additional quality-control check using multipoint mistyping analysis was done using Mendel 7.0 (20, 21) . These mistyping procedures identify both Mendelian errors and unlikely double recombinants. All genotypes flagged as potential errors were checked in the raw data. If the errors could not be resolved by reevaluation of the genotype calls, all genotypes that led to the Mendelian errors, or unlikely double recombinants, were removed if the probability was >0.6.
Statistical analysis. Unconditional logistic regression analyses were used to calculate adjusted odds ratios (aOR) and 95% confidence intervals to examine associations between each SNP and breast cancer while adjusting for other confounding factors (covariates). The potential confounding factors included in our analysis were age, education, Ashkenazi Jewish ancestry, BRCA1 and BRCA2 mutational status, smoking and alcohol history, body mass index (BMI; current and change from age 18 years), past use of oral contraceptives and hormone replacement therapy, parity, and menopausal status. Age, BMI (kg/m 2 ), and changes in BMI from age 18 years to present (kg/m 2 ) were coded as continuous variables, whereas tobacco history (V100 versus >100 cigarettes in lifetime), alcohol history (<12 versus z12 drinks in the last 12 months), oral contraceptive use and hormone therapy history (never versus ever), pregnancy (never versus ever), and menopausal status (menstrual period in the last 12 months: no/yes) were coded as binary 0 or 1 variables. Education was grouped into three levels and treated as a categorical variable: (a) grade school to associate degree, (b) college graduate to some college or professional school after college graduation, and (c) masters degree and higher. BRCA1 and BRCA2 mutational status were coded as binary variables; BRCA1/2 variants that confer risk were coded as a 1, negative results and polymorphisms were coded as 0, and variants of uncertain significance were treated as missing data. The dependent variable, breast cancer status, was coded as a binary outcome: 0 for unaffected, and 1 for those participants with either breast cancer or both breast and ovarian cancers.
Model selection was done on these covariates using a backward and forward stepwise logistic regression using the statistical package R: A Language and Environment for Statistical Computing (R Development Core Team, R Foundation for Statistical Computing, Vienna, Austria, 2006).
14 Putative confounding factors found to significantly improve the prediction of breast cancer status were then included as covariates in the final models in which SNPs were introduced individually. Each SNP was analyzed assuming log-additive and dominant genetic effects and adjusting for the significant covariates.
A haplotype analysis was done on SNPs of individual genes for which there were more than one significant SNP. The haplotyping frequencies were estimated using the Combining Loci Option of Mendel version 8.0 (20 -22) and haplotype counts for each individual were calculated using the QTL association option of Mendel (23) . Using the most frequent haplotype as a reference group, an additive model was used to introduce haplotype counts for a given gene into the logistic regression. A likelihood ratio test was used to investigate whether the haplotypes were associated with breast cancer.
Results
Participant selection. Our maximum sample size was 781, representing the total number of female participants enrolled in the Registry as of December 1, 2005. Twenty-seven women were excluded because they were not at high risk of breast cancer but rather were enrolled in the Registry because of high risk for other types of cancers (e.g., colorectal). Additionally, one participant withdrew consent from the Registry. Biological specimen collection was initiated in April 2002 (n = 753). Registry participants who had enrolled before that date were asked retrospectively to provide a blood specimen, and only 67 individuals did not participate. As a result, there were samples available from 686 individuals who were genotyped and used in the genotype quality-control procedures. In our statistical analyses, the sample was further reduced for the following reasons. To avoid problems due to statistical dependencies among family members, we selected only one family member per pedigree. Our sample was then age-trimmed so that the age range of unaffected participants matched that of the breast cancer patients, limiting our sample size to 501 individuals. We additionally excluded 16 participants who were affected with ovarian cancer alone and limited our analysis to those who either had breast cancer or breast and ovarian cancers or were unaffected (controls) for a sample size of 485. Finally, to avoid population stratification and because the number of nonCaucasians was relatively small (n = 86) and highly varied in ethnicity, we limited our analysis to those who were Caucasian for a final sample size of 399 individuals (see Fig. 3 ).
Participant characteristics. Analyses were done using all Caucasian participants selected [data set 1 (DS1), maximum sample size = 399], those not known to have BRCA1/2 risk conferring variants [data set 2 (DS2), maximum sample size = 333] and using all Caucasian individuals with known or inferred BRCA1 and BRCA2 test results [data set 3 (DS3), maximum sample size = 306]. Clinical and demographic characteristics of Caucasian breast cancer patients (n = 196) and controls (n = 203) are listed in Tables 2 and 3. As shown in [Tables 2 and 3 ], the affected and unaffected populations were very similar with respect to almost all variables, with nonsignificant P values when comparing education, income, tobacco and alcohol history, BMI, pregnancy, age of menopause, oral contraceptive use, and hormone replacement use. The mean age in the affected group was significantly greater (P < 0.0001), but ranges were similar. Although it is striking that a significantly high percentage of individuals were of Ashkenazi Jewish heritage in our study (41% of affected and 42% of unaffected participants), the percent of the population with Ashkenazi Jewish ancestry was similar in the two groups (P = 0.83).
Of note, the percentage of individuals not tested for BRCA1 and BRCA2 was significantly higher in the unaffected group (P < 0.0001). We suspect that this difference is related to an increased exposure to counseling regarding mutation testing in a person recently diagnosed with cancer. For those who were tested, the percentage of women who tested positive was not significantly different between cases and controls for either mutation.
Also of note are the significant differences between menstruation history in the last 12 months (P < 0.0001), reasons menstrual periods stopped, with increased likelihood of multiple therapies in the affected group (P < 0.0001), and increased prevalence of prophylactic mastectomies in the affected group (P < 0.0001). The fact that fewer affected women had menstrual periods than the unaffected women can be explained by the fact that the affected women are 4.5 years older on average. In addition, it is likely that more women diagnosed with cancer underwent combined radiation and chemotherapy as part of a treatment regimen for their cancer, effecting early menopause. None of these covariates were significant in the logistic regression (see below). Likewise, it is understandable why women diagnosed with cancer might be more likely to undergo prophylactic mastectomy. Clearly, prophylactic mastectomy is a consequence of cancer diagnosis not a cause. We do not expect these differences to have a significant effect on our analysis.
Although our study was not designed to directly match cases to controls, we did trim the sample to include only Caucasian participants and unaffected participants of the same age range as the affected group. All of the participants were enrolled in the UCLA Family Cancer Registry and thus were based in the same geographic region, Southern California. The high enrollment of Ashkenazi Jewish women is the result of this, as the Los Angeles metropolitan area has the second largest Jewish population in the United States. We did not compare Gail scores in our study because individuals in the affected group are known to have cancer. Likewise, we do not report BRCAPRO scores, but we do note that the total number of female first-degree relatives for the two groups is not significantly different (P = 0.55; Table 2 ), whereas the total number of affected first-degree female relatives is higher in the unaffected group (P = 0.01; Table 2 ), which is likely to be related to the criteria for entry in the study.
Model selection for hereditary and environmental covariates. Results from the backward and forward stepwise logistic regression with a = 0.20 as the criterion for their inclusion revealed the following covariates: age (aOR = 1.045 per year, P = 0.00021; 95% confidence interval, 1.02-1.07), Ashkenazi Jewish ancestry (aOR = 0.633, P = 0.067; 95% confidence interval, 0.37-0.90), and education (aOR = 1.464, P = 0.14; 95% confidence interval, 0.84-2.09, for masters or greater).
All other potential covariates were excluded. Although menopausal status (no menstrual period within the last 12 months) was significantly different in the unadjusted comparison (Table 3) , it was not significant as a covariate when age is also included in the model. All of the subsequent models described below in which SNPs were introduced individually were adjusted for age, education, and Ashkenazi Jewish ancestry.
Education was used, although it was not significant at a 0.05 level because of the important association of education and socioeconomic status with cancer incidence reported previously (24) . Likewise, Ashkenazi Jewish ancestry was included because it is a well-known risk factor for breast cancer, although it is unclear whether there is an increased risk of breast cancer in individuals with Ashkenazi Jewish ancestry who do not carry BRCA1 and BRCA2 mutations (25) . When using DS3, we also included BRCA1 and BRCA2 status because of their importance in DNA double-stranded repair, although these covariates were not significant in the logistic regression for our sample. Association of SNPs: additive and dominant models adjusted for covariates. Table 4 lists the ORs and P values for 12 SNPs where the P < 0.05 in one or more of the data sets assuming either a log-additive or a dominant genetic effect. These 12 SNPs were located within or near 8 genes: XRCC4 (intronic SNPs rs2075685, rs10474081, and rs1120476), XRCC2 (5 ¶ of gene; rs6464268), NBS1 (3 ¶-untranslated region SNP rs1063054), RAD21/hHR21 (intronic SNPs rs16888927, rs16888997, and rs16889040), RAD51/RAD51a (intronic SNP rs2619681), P53 (intronic SNP rs2909430), BRIP (synonymous coding SNP rs4986763), and ZNF350 (5 ¶ of gene; SNP rs8112515). We show the results for three data sets to help determine the effects of the SNPs adjusted for BRCA1 and BRCA2 mutation status. We also present results using a model where the allelic effects are additive on the log scale (additive model) as well as a dominant genetic model. In general, the results for these two models are similar, reflecting the fact that there are relatively few individuals for a homozygous for the minor allele.
The three intronic SNPs of RAD21/hHR21 have the strongest associations and gave consistent results with all three data sets as well as both genetic models. The minor allele of each of these three SNPs was inversely associated with breast cancer. The significance of the other SNPs depends on the model or data set. The minor allele of SNP rs4986763 in BRIP1 was inversely associated with an increase in risk in all three data sets assuming an additive genetic model. Interestingly, using dominant models, the three SNPs in XRCC4, rs1120476 (aOR = 2.04, P = 0.004 using DS1; aOR = 2.09, P = 0.006 using DS2), rs2075685 (aOR = 1.75, P = 0.015 using DS1; aOR = 1.94, P = 0.010 using DS2), and rs10474081 (aOR = 1.77, P = 0.020 using DS1; aOR = 1.75, P = 0.036 using DS2), are significantly associated with an increase in risk in DS1 and DS2 but show reduced effect sizes and diminished significance when BRCA1 and BRCA2 status are included as covariates (aOR = 1.75, P = 0.053 for rs1120476; aOR = 1.34, P = 0.291 for rs2075685; aOR = 1.26, P = 0.443 for rs10474081 using DS3). The same trend is seen using log-additive models for these SNPs. On the other hand, in XRCC2, SNP rs646426 shows increased effects and smaller P values when BRCA1 and BRCA2 status are included as covariates (log-additive models: aOR = 1.20, P = 0.340 using DS1; aOR = 1.20, P = 0.375 using DS3; and aOR = 1.66, P = 0.048; dominant models: aOR = 1.30, P = 0.268 using DS1; aOR = 1.30, P = 0.039 using DS2; and aOR = 2.23, P = 0.010 using DS3). The P values for the SNP rs2909430 in P53 increased dramatically and the aORs decreased when BRCA1 and BRCA2 status were included as covariates (log-additive models: aOR = 1.71, P = 0.034 using DS1; aOR = 1.58, P = 0.85 using DS2; and aOR = 1.42, P = 0.213; dominant models: aOR = 2.01, P = 0.011 using DS1; aOR = 1.86, P = 0.035 using DS2; and aOR = 1.71, P = 0.086 using DS3). SNP rs2619681 in RAD51/RAD51a was significantly associated only in a dominant genetic model when BRCA1 and BRCA2 status were included as covariates (aOR = 0.56, P = 0.043 using DS3). SNP rs81112515 5 ¶ of ZNF350 was only significantly associated under a log-additive model when all data from all the Caucasian participants were used (aOR = 0.63, P = 0.042 using DS1).
ORs for the SNPs rs16888927, rs16888997, and rs168889040 from RAD21/hHR21 vary based on the model, but the minor allele for each consistently remains significantly inversely associated with breast cancer in each data set and model. For example, the minor allele from rs16888997 is inversely associated with breast cancer, with an aOR of 0.56 (P = 0.003) for the additive model and 0.48 (P = 0.002) for the dominant model after adjusting for age, education, and Ashkenazi Jewish heritage in DS1, which includes all participants. This association persists for rs16888997 in DS2, in which individuals with known mutations for BRCA1/2 are excluded, with an aOR of 0.53 (P = 0.003) and 0.45 (P = 0.002). Thus, the inverse association of this SNP with breast cancer is not restricted to individuals who carry risk from a BRCA1/2 mutation. Finally, rs16888997 is again inversely associated with breast cancer with aOR of 0.53 (P = 0.007) in the additive model and 0.43 (P = 0.003) in the dominant model, after adjusting for BRCA1 and BRCA2 status, in addition to age, education, and Ashkenazi Jewish ancestry, using the population of individuals with known BRCA1 and BRCA2 status (DS3). Thus, the aOR values are not biased by the differences in missing data in test results. By contrast, rs2909430 from TP53 was found to be significantly inversely associated with breast cancer in models adjusting for age, education, and Ashkenazi Jewish ancestry, with aOR 1.71 (P = 0.034 additive and P = 0.011 dominant), whereas this association was lost after adjusting for BRCA1 and BRCA2 status (P = 0.213 additive and P = 0.086 dominant).
We adjusted for multiple testing by setting the tolerated false discovery rate at 15% (26) . Using this criterion, we find that the following SNPs are significant after adjusting for multiple testing: rs1120476 (dominant model, DS1 and DS2) in XRCC4, rs16888927 (dominant model, DS1-DS3), rs16888997 (additive and dominant models, DS1-DS3), rs16889040 (dominant model, DS2 and DS3) in RAD21, and rs4986763 (additive and dominant models, DS2) in BRIP1. These results are designated in Table 4 .
Cumulative association and haplotype analysis. We examined additive models of cumulative risk for the 12 SNPs found to have an association with breast cancer after adjusting for age, education, and Ashkenazi Jewish ancestry. For SNPs in which the minor allele was found to be inversely associated with breast cancer, we used the major allele as the ''high-risk'' allele. We found a cumulative association with breast cancer for the additive effect of the ''high-risk'' alleles from these 12 SNPs. The trend in the number of risk alleles with the aOR for presence of each additional risk allele is 1.13 (P = 0.017).
Because several SNPs were implicated in the XRCC4 and RAD21 genes, we tested the association of the haplotypes with breast cancer using DS1 adjusting for age, education, and Ashkenazi Jewish heritage. Using an additive model, we found that the C-A-A haplotype of RAD21 (SNPs rs16888927, rs16888997, and rs889040) was positively associated with breast cancer (P = 0.0068). Likewise, the T-G-G and T-G-A haplotypes of XRCC4 (SNPs rs2075685, rs10474081, and rs1120476) were positively associated with breast cancer (P = 0.0330). However, for both genes, the haplotypes did not result in a more significant association than the corresponding allele of the most associated SNP.
Discussion
Our results suggest that SNPs within or near several DSBR DNA repair pathway genes are associated with breast cancer in individuals from a high-risk population. After adjustment for multiple testing, 5 SNPs remain significant when the false discovery rate is set at 15%. Although they may be falsepositives, the results of all 12 SNPs identified with P V 0.05 in any of the models are potentially useful in generating hypotheses regarding the role of the DSBR pathways in breast cancer susceptibility.
Our most significant results are for three SNPs found in RAD21. The three SNPs are in linkage disequilibrium and any one of them is sufficient to account for the association. Results from a large-scale case-control association study using >25,000 SNPs, located within f16,000 genes, lend support for RAD21 as a susceptibility gene for breast cancer (27) . RAD21 is implicated in homologous recombination-mediated DSB DNA repair and plays a role in cell cycle regulation (28) . RAD21 is also involved in the mitochondrial apoptosis pathway and most recently has been shown to play an important role in predicting the outcome in breast cancer patients with supraclavicular lymph node metastases (29) .
It is of note that the minor alleles from SNPs within XRCC4, XRCC2, and NBS1 are positively associated with breast cancer, whereas the minor alleles from SNPs within the RAD21/ hHR21, RAD51/RAD51a, BRIP1, and ZNF350 are inversely associated with breast cancer. Inverse associations have been reported previously in DNA repair genes. For example, the R194W polymorphism in the base excision repair gene XRCC1 has been shown to be associated with reduced risk of bladder cancer (30) , and the codon 399 Arg-to-Gln polymorphism has been shown to be associated with reduced risk of breast cancer in African Americans who smoke tobacco (31) , suggesting that the SNP may modulate effects of environmental exposures. An inverse association may either mean that the minor allele confers protection or that the major allele confers risk. The functional significance of what may be happening is not clear. The minor allele could be involved in a regulatory pathway and actually may confer protection, or the SNP may be in linkage disequilibrium with another SNP in which the minor allele confers risk. It is important to remember that both cases and controls in our study come from a high-risk breast cancer population. With this study design, controls are representatives of a resistant population, suggesting the possibility of protective SNPs. These polymorphisms could be responsible for a woman with several risk factors for breast cancer to remain cancer-free. Alternatively, the major allele may be the more recent polymorphism that has increased in frequency due to random drift.
Several of the SNPs in our study that were shown to be associated with cancer risk in this high-risk population have been previously implicated in breast cancer. The TP53 SNP rs2909430 (32) and the XRCC4 SNP rs2075685 (9) were associated with breast cancer in two independent case-control studies. Some SNPs identified in our study have been implicated in other types of cancer. For example, XRCC2 SNPs rs321834 and rs6464268 have been found to be associated with bladder cancer risk (33) .
DNA repair SNPs are also candidate modifiers of highly penetrant genes. For example, SNPs of DSBR genes RAD51 (34 -37) and ATM (38) , as well as MDM2, a regulator of p53 (39), have been implicated as possible modifiers of BRCA1/ 2-associated breast cancer risk. The BRCA1 gene induces expression of RAD21 (40) . Unfortunately, the number of individuals with BRCA1 risk variants (n = 42) or BRCA2 risk variants (n = 24) are too small to test for gene-gene interactions in this study. In the future, we plan to examine the question of SNP-BRCA interactions once there are sufficient numbers of individuals in the Registry with BRCA1/2 risk variants.
Some of the genes studied here have been shown previously to be associated with breast cancer but with different SNPs than those described here. These genes and SNPs include XRCC4: rs1805377 (9), ZNF350: rs4986771 (11), TP53: rs9894946, rs1625895, and rs1614984 (32), MRE11A: rs601341 (41), and XRCC2: rs1799794 (7, 8, 41, 42) . SNP rs1614984 from the TP53 gene is in linkage disequilibrium with rs2909430, one of the SNPs found to be associated with breast cancer in our study, with R 2 = 0.803, based on analyses of the CEPH HapMap data. In addition, SNPs from genes XRCC2 have also been associated with increased risk in pancreatic cancer (43) .
Some other SNPs previously observed to be associated were tested in our study and were not significant. These SNPs include BRCA1: rs799917 (44), BRCA2: rs144848 (11), and XRCC4: rs2075686 (9) . A candidate gene study examined 710 tag SNPs in 120 candidate genes in 4,400 breast cancer cases and 4,400 controls and found several SNPs associated with breast cancer (14) . SNPs significantly associated with breast cancer arose from different pathways, including the cell cycle control pathway, steroid hormone metabolism, and signaling and DNA repair pathways. The following SNPs were in both our study and theirs: rs799917 and rs3737559 from BRCA1, rs144848, rs542551, and rs2126042 from BRCA2, rs2191249, rs4988344, rs4968451, and rs2378908 from BRIP1, rs2619681 and rs11852786 from RAD51, rs6470522 from NBS1, and rs3218536, rs3218499, and rs3218374 from XRCC2 pathways. None of these SNPs were found to be significant in the Pharoah et al. study (14) and only one was found significantly associated with familial breast cancer in our study: rs2619681 from the RAD51 gene. RAD21 and XRCC4, the genes with the strongest support in our study, were not examined in the Pharoah et al. study.
In another candidate gene study examining 12 SNPs from the DNA repair pathways in 1,109 women with breast cancer and 1,177 age-matched healthy controls, SNPs rs1801320 and rs1801321 from the RAD51 gene were not found to be significantly associated with breast cancer (41) . It is of note that these SNPs are located f1,600 bp away from the SNP rs2619681 in RAD51, which was found to be significantly associated in our study. SNPs that were found to be significant in the Loizidou et al. study included rs1799944 from BRCA2 and rs601341 from MRE11A. The MRE11A locus was f20,000 bp from the SNPs of MRE11A examined in our study and not found to be significant. The BRCA2 SNP rs1799944 was only 430 bp away from rs1801406, which was analyzed in our sample and not found to be significantly associated.
Hunter et al. (45) examined the association of a genomewide panel of polymorphisms with sporadic breast cancer in a population of postmenopausal women of European ancestry. The strongest support came from SNPs in the FGFR2 and RELN genes, which are not involved in DNA repair pathways. This study found no evidence of association in regions containing DNA repair genes. Notable differences have been found before when comparing the association of polymorphisms from DNA repair genes with familial breast cancer in a high-risk population with the association of these polymorphisms with sporadic breast cancer in the general population. Some of these results may be false-positives in one study, but it is also possible that polymorphisms that confer risk in familial breast cancer may be different than the genes that confer breast cancer in sporadic cases (46) . By contrast, some recent genome-wide association studies have examined the association of polymorphisms with familial breast cancer in high-risk populations, with the rationale that these individuals are more likely to carry susceptibility alleles. Gold et al. (47) confirmed the association of polymorphisms from FGFR2 in a population of 249 high-risk Ashkenazi Jewish breast cancer patients testing negative for both BRCA1 and BRCA2 and 299 cancer-free Ashkenazi Jewish controls and identified a new locus in chromosome 6q22.33 associated with breast cancer in this population. Easton et al. (48) examined 227,876 tag SNPs from the whole genome in 408 cases of invasive breast cancer, with strong family history (at least 2 affected women first-degree relatives), and 400 controls and found 6 SNPs significantly associated with breast cancer (P < 10 -5 ). These SNPs were from the following genes: FGFR2, TNRC9 (unknown function), lymphocyte specific protein (LSP1), and H19 (associated with insulin growth factor gene regulation). Neither study reported significant associations at or near DSBR genes.
There are several reasons that our results differ from some of the results of the studies we mentioned in the preceding paragraphs. It is possible that the associations found in the original studies represent type 1 errors or artifacts of hidden ethnic differences between cases and controls. It is also possible that our lack of support for association of breast cancer with these SNPs is due to an insufficient sample size to detect moderately small risks. However, our results could also be due to the special characteristics of the unaffected participants in our study. Because the controls come from the UCLA Familial Cancer Registry, they are individuals at high risk with a family history of breast cancer and may harbor many of the same risk variants as affected participants.
The characteristics of the study sample warrant additional discussion, as the unique aspects bear on both the interpretation and the generalizability of the inferences. The UCLA Family Cancer Registry is a clinic-based repository of information about people who have had cancer or have a strong family history of cancer. This information can include complete pedigree data, survey data on lifestyles, health behaviors, biological specimens such as tissue or blood samples, and results of genetic susceptibility testing. The careful documentation of lifestyles and behaviors as well as demographics allowed us to examine the effects of SNPs adjusted for these covariates. The Family Cancer Registry enrolls individuals who either (a) have a family history of cancer, defined as at least two individuals with the same primary cancer or cancers that are known to be related (e.g., breast and ovarian) and who are at least second-degree relatives of each other, or (b) have a documented, known susceptibility cancer gene (e.g., BRCA1). Registry participants may or may not have had cancer themselves. We chose this clinic-based resource because it allows for investigation of genetic association with breast cancer in a high-risk population.
Selecting cases and controls from the Family Cancer Registry leads to a nested study design with specific consequences. It conditions both affected and unaffected women on having a high risk of a familial form of breast cancer. This study design has a disadvantage over using women selected as cases or controls from the general population. The power to detect interactions between the implicated SNPs and other breast cancer risk factors has been reduced. In effect, we have over matched our cases and controls on these other risk factors. Indeed, we find that the affected and unaffected participants in our study had similar prevalence of most of the well-known risk factors for breast cancer. For example, the proportion of women of Ashkenazi Jewish heritage was quite high in our population sample and this prevalence was similar in the unaffected (42%) and affected (41%) groups.
There are also advantages to the conditioning on having a high risk of a familial form of breast cancer. This design should increase the likelihood of detecting polymorphisms that may protect against breast cancer. However, with the nested design, we also must guard against direct extrapolation of our findings to the general population. This caution is particularly important for those polymorphisms that may be associated with protection against breast cancer. Because unaffected women in the general population are not ''exposed'' to the same risks as controls in this study, these protective polymorphisms may not be detected.
In conclusion, we identified several polymorphisms in the RAD21 and XRCC4 genes as well as others involved in doublestranded DNA repair pathways that modulate breast cancer susceptibility in a high-risk population. Although none of these polymorphisms have aORs close to the same magnitude as BRCA1 and BRCA2, these results are helpful in generating hypotheses about parts of the DNA repair pathway that may play a role in carcinogenesis and may help explain why some individuals with familial risk of breast cancer get breast cancer why others with the same risk factors do not. Further studies in similar populations with larger numbers of known mutation carriers are warranted.
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